A phase 2 study of combination neoadjuvant chemotherapy with gemcitabine S-1 and leucovorin in patients with borderline and locally advanced pancreatic cancer - NAC-GS

The University of Tokyo Hospital0 个研究点目标入组 24 人开始时间: 2013年12月4日最近更新: 2023年10月17日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方: The University of Tokyo Hospital
入组人数: 24

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

Twenty-four patients with PC (21 BR and 3 LA) were enrolled. Response rate and disease control rate of NAC were 17.4 and 87.0%. Grade 3 and 4 toxicities involved neutropenia (34.8%), anorexia (17.4%), and mucositis (17.4%). Serum CA19-9 level decreased by 52.2%. Resection rate was 60.9% after the median of 4 cycles and R0 resection rate was 76.5% in patients undergoing laparotomy. NAC-GSL is a feasible treatment option for BR and LAPC.

研究设计

研究类型: Interventional

入排标准

年龄范围: 20years-old 至 ot applicable（—）
性别: All

入选标准

未提供

排除标准

•1) Patients with systolic blood pressure < 100mmHg 2) Patients with an active concomitant infection 3) Patients with digestive ulcer or gastrointestinal bleeding, severe heart or renal disease 4) Patients with an active pulmonary fibrosis or interstitial pneumonia 5) Patients with severe diarrhea 6) Pregnant, lactating female and patients of reproductive potential who did not use effective contraception 7) Patients with uncontrollable massive pleural effusion or massive ascites 8) Patients with an active concomitant malignancy 9) Inappropriate patients for entry on this study in the judgement of the investigator

研究者

发起方

The University of Tokyo Hospital

相似试验

尚未招募

不适用

Phase 2 study of combination chemotherapy(VBL/PSL, MTX, 6MP) in patients with primary untreated adult langerhans cell histiocytosisadult langerhans cell histiocytosis

JPRN-UMIN000006016Department of Hematology, International Medical Center, Saitama Medical University5

已完成

2 期

A Phase II study of neoadjuvant combination chemotherapy with TS-1, cisplatin and Paclitaxel (PCS) for resectable advanced gastric cancer.resectable advanced gastric cancer

JPRN-UMIN000006674Kinki University Faculty of Medicine20

已完成

2 期

A Phase II study of combination chemotherapy including Bortezomib in pediatric patients with relapsed acute lymphoblastic leukemia (Investigator-initiated clinical trial)A high-risk group of pediatric patients with first relapse of ALLor refractory ALL (patients who develop 2nd or subsequent relapse, relapse after hematopoietic cell transplantation or fail to achieve remission induction with one or more therapies).

JPRN-UMIN000023815Department of Pediatric Oncology, National Cancer Center Hospital22

已完成

2 期

Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the PenisPenile Cancer

NCT00512096M.D. Anderson Cancer Center30

招募中

2 期

Multicenter phase II study of combination chemotherapy with IRIS and Cetuximab as second line therapy in patient with colorectal cancercolorectal cancer

JPRN-UMIN000006793ippon Medical School Musashikosugi Hospital40